A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND DOSE-RESPONSE RELATIONSHIP OF MULTIPLE DOSES OF GSK2269557 ADMINISTERED AS A DRY POWDER TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS: